UY30192A1 - Nuevo uso - Google Patents
Nuevo usoInfo
- Publication number
- UY30192A1 UY30192A1 UY30192A UY30192A UY30192A1 UY 30192 A1 UY30192 A1 UY 30192A1 UY 30192 A UY30192 A UY 30192A UY 30192 A UY30192 A UY 30192A UY 30192 A1 UY30192 A1 UY 30192A1
- Authority
- UY
- Uruguay
- Prior art keywords
- och3
- fluoro
- prevention
- hydrogen
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se refiere a un nuevo uso de un compuesto de formula (I) donde R1 es NH2, piperazin-1-ilo, 4-metilpiperazin-1-ilo, 4-metil-1,4-diazepam-1-ilo o 4-etilpiperazin-1-ilo; R2 es hidrogeno, fluoro, CH3,CH2Ch3, OCH3, OCH3, CF3 u OCF3; R3 es hidrogeno, CH3 o fluoro; como una base libre o una sal farmacéuticamente aceptable del mismo, en la fabricacion de un medicamento para la prevencion y/o tratamiento de trastornos oseos, osteoporosis y para aumentar la formacion osea, densidad mineral osea. La presente invencion se refiere además a un método para prevencion y/o tratamiento de esos trastornos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78025206P | 2006-03-08 | 2006-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30192A1 true UY30192A1 (es) | 2007-10-31 |
Family
ID=38475142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30192A UY30192A1 (es) | 2006-03-08 | 2007-03-07 | Nuevo uso |
Country Status (16)
Country | Link |
---|---|
US (1) | US7576093B2 (es) |
EP (1) | EP1993550A4 (es) |
JP (1) | JP2009529041A (es) |
KR (1) | KR20080114717A (es) |
CN (1) | CN101394851A (es) |
AR (1) | AR059754A1 (es) |
AU (1) | AU2007222199A1 (es) |
BR (1) | BRPI0708619A2 (es) |
CA (1) | CA2644751A1 (es) |
IL (1) | IL193484A0 (es) |
MX (1) | MX2008011417A (es) |
NO (1) | NO20084182L (es) |
TW (1) | TW200800203A (es) |
UY (1) | UY30192A1 (es) |
WO (1) | WO2007102770A1 (es) |
ZA (1) | ZA200807234B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100137330A1 (en) * | 2007-03-08 | 2010-06-03 | Ratan Bhat | Use |
WO2010054398A1 (en) | 2008-11-10 | 2010-05-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8841308B2 (en) | 2008-12-19 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Pyrazin-2-amines useful as inhibitors of ATR kinase |
BR112012017884A2 (pt) | 2010-01-19 | 2019-09-24 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, derivado de pirazina, métodos para o tratamento ou prevenção, para promoção óssea, e, para tratar lesões ósseas em cânceres |
WO2011143423A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
AU2011253021A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of ATR kinase |
EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
EP2569313A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CA2803802A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
JP2014510151A (ja) | 2011-04-05 | 2014-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ(trakinase)阻害剤として有用なアミノピラジン化合物 |
US9273029B2 (en) * | 2011-05-23 | 2016-03-01 | Merck Patent Gmbh | Pyridine-and pyrazine derivatives |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
US9096602B2 (en) | 2011-06-22 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors |
SG11201401095YA (en) | 2011-09-30 | 2014-04-28 | Vertex Pharma | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
CA2850564A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9035053B2 (en) | 2011-09-30 | 2015-05-19 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
US8846918B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2776422A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776419B1 (en) | 2011-11-09 | 2016-05-11 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
LT2833973T (lt) | 2012-04-05 | 2018-02-12 | Vertex Pharmaceuticals Incorporated | Junginiai, tinkami naudoti kaip atr kinazės inhibitoriai, ir jų kombinuotas gydymas |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
DK2941432T3 (en) | 2012-12-07 | 2018-06-14 | Vertex Pharma | 2-amino-6-fluoro-N- (5-fluoro-4- (4- (4- (oxetan-3-yl) piperazine-1-carbonyl) piperidin-1-yl) pyridine-3-yl) pyrazolo [ 1,5ALPHA] PYRIMIDIN-3-CARBOXAMIDE AS ATR-KINASE INHIBITOR |
RS60371B1 (sr) | 2013-03-14 | 2020-07-31 | Brigham & Womens Hospital Inc | Sastavi i postupci za ekspanziju i kultivisanje epitelnih matičnih ćelija |
JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
US10160760B2 (en) | 2013-12-06 | 2018-12-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CN103804312B (zh) * | 2014-02-17 | 2016-04-20 | 四川百利药业有限责任公司 | 一类氮杂环化合物及其制备方法和用途 |
SG11201610197XA (en) | 2014-06-05 | 2017-01-27 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
RS59054B1 (sr) | 2014-06-17 | 2019-08-30 | Vertex Pharma | Postupak za lečenje raka korišćenjem kombinacije chk1 i atr inhibitora |
JP6773645B2 (ja) | 2014-09-03 | 2020-10-21 | ザ ブリガム アンド ウィミンズ ホスピタル,インコーポレイテッド | 聴覚障害の治療のための内耳毛細胞を生成するための組成物、システムおよび方法 |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
JP2019506153A (ja) | 2016-01-08 | 2019-03-07 | マサチューセッツ インスティテュート オブ テクノロジー | 分化した腸内分泌細胞およびインスリン産生細胞の作製 |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
MX2019007890A (es) | 2016-12-30 | 2020-01-20 | Frequency Therapeutics Inc | Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte. |
WO2020037323A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
EP3837351A1 (en) | 2018-08-17 | 2021-06-23 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4783532B2 (ja) | 2000-02-05 | 2011-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Erkのインヒビターとして有用なピラゾール組成物 |
SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
SE0102439D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
JP4237066B2 (ja) * | 2002-01-10 | 2009-03-11 | エフ.ホフマン−ラ ロシュ アーゲー | 骨形成を増加させるための薬物の製造におけるGSK−3β阻害剤の使用 |
PT1483265E (pt) | 2002-03-05 | 2007-01-31 | Lilly Co Eli | Derivados de purina como inibidores de quinase |
SE0203752D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
AU2004274861A1 (en) | 2003-06-06 | 2005-03-31 | Wyeth | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby |
CN1835755A (zh) | 2003-08-13 | 2006-09-20 | 希龙公司 | Gsk-3抑制剂及其用途 |
US20050064044A1 (en) * | 2003-09-19 | 2005-03-24 | Georges Rawadi | GSK-3beta inhibitors in the treatment of bone-related diseases |
-
2007
- 2007-03-02 TW TW096107083A patent/TW200800203A/zh unknown
- 2007-03-06 AR ARP070100917A patent/AR059754A1/es not_active Application Discontinuation
- 2007-03-06 KR KR1020087021787A patent/KR20080114717A/ko not_active Application Discontinuation
- 2007-03-06 CN CNA2007800079632A patent/CN101394851A/zh active Pending
- 2007-03-06 AU AU2007222199A patent/AU2007222199A1/en not_active Abandoned
- 2007-03-06 EP EP07716035A patent/EP1993550A4/en not_active Withdrawn
- 2007-03-06 BR BRPI0708619-9A patent/BRPI0708619A2/pt not_active IP Right Cessation
- 2007-03-06 MX MX2008011417A patent/MX2008011417A/es not_active Application Discontinuation
- 2007-03-06 JP JP2008558230A patent/JP2009529041A/ja active Pending
- 2007-03-06 WO PCT/SE2007/000216 patent/WO2007102770A1/en active Application Filing
- 2007-03-06 CA CA002644751A patent/CA2644751A1/en not_active Abandoned
- 2007-03-07 UY UY30192A patent/UY30192A1/es not_active Application Discontinuation
- 2007-03-08 US US11/683,458 patent/US7576093B2/en not_active Expired - Fee Related
-
2008
- 2008-08-14 IL IL193484A patent/IL193484A0/en unknown
- 2008-08-21 ZA ZA200807234A patent/ZA200807234B/xx unknown
- 2008-10-06 NO NO20084182A patent/NO20084182L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20070213322A1 (en) | 2007-09-13 |
WO2007102770A8 (en) | 2008-01-31 |
TW200800203A (en) | 2008-01-01 |
ZA200807234B (en) | 2009-09-30 |
MX2008011417A (es) | 2008-09-22 |
CN101394851A (zh) | 2009-03-25 |
KR20080114717A (ko) | 2008-12-31 |
AU2007222199A1 (en) | 2007-09-13 |
CA2644751A1 (en) | 2007-09-13 |
BRPI0708619A2 (pt) | 2011-06-07 |
IL193484A0 (en) | 2009-08-03 |
WO2007102770A1 (en) | 2007-09-13 |
AR059754A1 (es) | 2008-04-30 |
JP2009529041A (ja) | 2009-08-13 |
US7576093B2 (en) | 2009-08-18 |
EP1993550A1 (en) | 2008-11-26 |
EP1993550A4 (en) | 2010-04-21 |
NO20084182L (no) | 2008-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30192A1 (es) | Nuevo uso | |
TNSN08283A1 (en) | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | |
ECSP055684A (es) | Antagonistas del receptor opiode | |
TN2012000062A1 (en) | Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer | |
DK1678166T3 (da) | Proteinkinaseinhibitorer | |
MY147786A (en) | Substituted morpholine and thiomorpholine derivatives | |
TW200720266A (en) | Benzodioxane and benzodioxolan derivatives and uses thereof | |
TW200730506A (en) | Compounds and uses thereof | |
TW200531694A (en) | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists | |
ATE457988T1 (de) | A2a-adenosin-rezeptor-antagonisten | |
TW200806300A (en) | New therapeutic combinations for the treatment of depression | |
PH12013502359A1 (en) | Carboxamide compounds and their use as calpain inhibitors | |
TW200800943A (en) | Indane derivatives as MCH receptor antagonists | |
GEP20115222B (en) | New pharmaceutical compounds | |
MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
MX2010004312A (es) | Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso. | |
SE0401342D0 (sv) | Therapeutic compounds | |
MX2012006962A (es) | Inhibidores de la esfingosina quinasa. | |
UY31159A1 (es) | Derivados de quinolina, métodos para su fabricación, composiciones farmacéuticas de los mismos y usos de los mismos | |
TW200728291A (en) | Amide derivatives | |
TW200640465A (en) | New pharmaceutically active compounds for the treatment of respiratory diseases | |
TW200806321A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
TW200833697A (en) | Spiro-piperidine derivatives | |
MX2009005544A (es) | Indoles. | |
UY28993A1 (es) | Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.- |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20170529 |